中文

TG Therapeutics (TGTX)

Biotech

Close on Nov 10, 2026 (from our latest Long View update): $64.26

Market value
$9.7Bat the Nov 10 close
Revenue growth
+69%12 months to Sep 30, 2026 (10-Q)
FCF margin
10%12 months to Sep 30, 2026 (10-Q)
Net debt
$189Mat Sep 30, 2026
Worst fall since listing
−99.6%May 4, 2010 to Dec 29, 2011; not back to that high (−72.2% now)

About the company

Latest

  • Up 5.9% Quarterly
    TG Therapeutics Q3 2026: Briumvi target raised again, but sales growth slows to 2% from Q2

The Long View

TG was a cancer-drug developer until April 2022, when it announced the withdrawal of its lymphoma drug Ukoniq and the combination filing in leukaemia after trial survival data turned against it.

Self-funding

▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash

Updated Nov 11, 2026

Read the Long View →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for TG Therapeutics, FY2011–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $0.2M in FY2016 to $616M in FY2025. Free cash flow was positive in 0 of the 15 years shown; FY2025: −$25M. Each year's figures are in the table below. −$500M−$250M$0$250M$500M$750M ’11 ’13 ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $0.2M in FY2016 to $616M in FY2025.

Free cash flow was positive in 0 of the 15 years shown; FY2025: −$25M.

Margins

Operating margin was 20% in FY2025, vs −179996% in FY2020. Each year's figures are in the table below. −200000%−150000%−100000%−50000%0%50000% ’16’17’18’19’20’21’22’23’24’25

Operating margin was 20% in FY2025, vs −179996% in FY2020.

Diluted share count

The diluted share count rose 40% from FY2020 to FY2025, to 161M. Each year's figures are in the table below. 100M120M140M160M180M ’20’21’22’23’24’25

The diluted share count rose 40% from FY2020 to FY2025, to 161M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$616M—20%$447M−$25M$0.2M−$25M
FY2024$329M—13%$23M−$41M$0.0M−$41M
FY2023$234M—9%$13M−$31M$0−$31M
FY2022$3M—−7839%−$224M−$176M$0.0M−$176M
FY2021$7M—−5154%−$348M−$296M$0.4M−$296M
FY2020$0.2M—−179996%−$279M−$215M$0.4M−$215M
FY2019$0.2M—−111220%−$173M−$133M$0.1M−$133M
FY2018$0.2M—−114737%−$173M−$129M$0.1M−$129M
FY2017$0.2M—−78100%−$118M−$94M$0.0M−$94M
FY2016$0.2M—−51953%−$78M−$62M$0.3M−$62M
FY2015———−$63M−$45M$0.0M−$45M
FY2014———−$56M−$35M$0.0M−$35M
FY2013———−$20M−$11M$0.0M−$11M
FY2012———−$18M−$5M$0.0M−$5M
FY2011———−$0.9M−$0.1M$0−$0.1M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY2025161M$142M$246M$65M—$91M
FY2024160M$311M$244M$43M—$9M
FY2023149M$218M$100M$38M—$0
FY2022135M$162M$71M$45M—$0
FY2021132M$315M$68M$61M——
FY2020115M$605M$30M$80M——
FY2019—$140M$29M$11M——
FY2018—$69M$0$13M——
FY2017—$85M$0.1M$16M——
FY2016—$45M$0.1M$8M——
FY2015—$77M$0.2M$16M—$0
FY2014—$79M$0.3M$21M—$0
FY2013—$40M$0.7M$5M—$0.1M
FY2012—$16M$3M$3M—$0.1M
FY2011—$10M$4M$0.1M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 11, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

  • FY2014 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
  • FY2015 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
  • FY2016 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
  • FY2017 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
  • FY2018 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
  • FY2019 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
  • FY2020 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.

Returns by year

YearTGTXS&P 500
2019+170.7%+31.5%
2020+368.7%+18.4%
2021−63.5%+28.7%
2022−37.7%−18.1%
2023+44.4%+26.3%
2024+76.2%+25.0%
2025−1.0%+17.9%
2026 to date+117.7%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about TG Therapeutics

How does TG Therapeutics make money?
It sells one approved drug, Briumvi (ublituximab), for relapsing multiple sclerosis. In 2025 revenue was $616.3M, 96% of it from US sales through four specialty distributors; its partner Neuraxpharm sells Briumvi in licensed territories outside the US and pays royalties. More in the Long View →
How does Briumvi compare with other MS drugs?
Like Roche's Ocrevus and Novartis's Kesimpta, it is an anti-CD20 antibody: it targets CD20, a protein on certain B cells, and depletes those cells; its precise mechanism in MS is unknown. It is infused twice a year after the starting doses. More in the Long View →
How long is Briumvi protected?
It is eligible for 12 years of US biologic exclusivity from its approval, to December 2034. The original US composition-of-matter patent (covering the drug itself) expires in 2029, before any extension; newer US patents extend composition-of-matter protection to 2042. More in the Long View →
What does TG depend on?
One product, one licensor, one main manufacturer (Samsung Biologics) and one secured lender. TG sells mainly through four unnamed specialty distributors; the largest alone was 46% of gross product revenue in Q3 2026. More in the Long View →
How has TG financed itself since Briumvi's launch?
TG has raised money through share sales, an upfront licence payment from Neuraxpharm and secured borrowing. Its $750M loan in March 2026 refinanced a $250M loan, and it has spent $300M on buybacks since August 2024. More in the Long View →

Disclosure: one or more of our editors own shares of TG Therapeutics (TGTX) as a long-term investment.